Salarius Pharmaceuticals (SLRX) announces that on September 4, 2025 the Company received notification from The Nasdaq Stock Market that it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement. By meeting the Minimum Bid Price Requirement, Salarius has achieved one of the milestones in regaining compliance with all Nasdaq continued listing standards. As previously disclosed on August 27, 2025, Salarius has until October 20, 2025 to regain compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard Requirement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLRX:
- Salarius Pharmaceuticals Granted Nasdaq Compliance Extension
- Salarius Pharmaceuticals Files Prospectus for Stock Offering
- Decoy Therapeutics Reports Financial Downturn Amid Funding Challenges
- Salarius Pharmaceuticals Appoints New Acting CEO
- Upcoming Stock Splits This Week (August 18 to August 22) – Stay Invested